EUVIMEDEUVIMED entdecken
Crossref

91 Circulating inflammatory proteins and the risk of age-related macular degeneration: A bidirectional Mendelian randomization study

Tianyu Wang, Jinbo Chen, Junliang Wang, Yanyan Zhang, Wei Mao, Quanyong Yi

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112678 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Tianyu Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Ningbo Eye Institute, Ningbo Eye Hospital, Wenzhou Medical University, Ningbo, China. Hauptthemen laut MEDLINE: Macular Degeneration, Mendelian Randomization Analysis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Previous observational studies have indicated a correlation between circulating inflammatory proteins and age-related macular degeneration (AMD), yet the causal nature of this relationship remains uncertain. This study aims to investigate the causal link between circulating inflammatory proteins and AMD utilizing a bidirectional two-sample Mendelian randomization approach. The findings indicated that elevated levels of four circulating inflammatory proteins, including C-C Motif Chemokine Ligand 11 (CCL11), Signaling Lymphocytic Activation Molecule Family Member 1 (SLAMF1), TNF Superfamily Member 11 (TRANCE) and Vascular Endothelial Growth Factor A (VEGF-A) lead to the increased risk of AMD, while increased levels of two circulating inflammatory proteins, including Fibroblast Growth Factor 19 (FGF-19) and Interleukin 10 Receptor Subunit Alpha (IL-10RA), resulted in the decreased risk of AMD. Conversely, the results from reverse Mendelian randomization suggested that the presence of AMD lead to the reduction in levels of 15 circulating inflammatory proteins. The findings of this study support the association between elevated levels of circulating inflammatory proteins and the risk of AMD, as well as the potential impact of AMD on reducing circulating inflammatory protein levels. CCL11, SLAMF1, TRANCE and VEGF-A are identified as potential molecular markers in the progression of AMD. These results offer a novel molecular therapeutic target for the prevention and treatment of AMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macular DegenerationMendelian Randomization AnalysisHumansBiomarkersVascular Endothelial Growth Factor AInflammation MediatorsPolymorphism, Single Nucleotide

Stichwörter der Autor:innen

AMDCausal relationshipCirculating inflammatory proteinsMendelian randomizationSNP

Substanzen

BiomarkersVascular Endothelial Growth Factor AInflammation Mediators

Autor:innen und Institutionen

  • Department of Ophthalmology, Ningbo Eye Institute, Ningbo Eye Hospital, Wenzhou Medical University, Ningbo, China.
  • Department of Ophthalmology, Ningbo Eye Institute, Ningbo Eye Hospital, Wenzhou Medical University, Ningbo, China. Electronic address: maowei0911@163.com.
  • Department of Ophthalmology, Ningbo Eye Institute, Ningbo Eye Hospital, Wenzhou Medical University, Ningbo, China. Electronic address: quanyong__yi@163.com.

Zitieren

APA

Wang, T., Chen, J., Wang, J., Zhang, Y., Mao, W., & Yi, Q. (2024). 91 Circulating inflammatory proteins and the risk of age-related macular degeneration: A bidirectional Mendelian randomization study. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112678

Vancouver

Wang T, Chen J, Wang J, Zhang Y, Mao W, Yi Q. 91 Circulating inflammatory proteins and the risk of age-related macular degeneration: A bidirectional Mendelian randomization study. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112678

BibTeX
@article{Wang2024,
  author = {Wang, Tianyu and Chen, Jinbo and Wang, Junliang and Zhang, Yanyan and Mao, Wei and Yi, Quanyong},
  title = {91 Circulating inflammatory proteins and the risk of age-related macular degeneration: A bidirectional Mendelian randomization study},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112678}
}
Kostenlos starten →